Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Rainer, M; Wuschitz, A; Jagsch, C; Erb, C; Chirikdjian, JJ; Mucke, HA.
Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study.
J Neural Transm (Vienna). 2011; 118(8): 1255-9.
Doi: 10.1007/s00702-011-0623-8
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Jagsch Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this 'real-life' setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Alzheimer Disease - diagnosis, drug therapy, psychology
- Female - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Memantine - therapeutic use
- Product Surveillance, Postmarketing - methods
- Prospective Studies - administration & dosage
- Severity of Illness Index - administration & dosage
- Treatment Outcome - administration & dosage